Industry Veteran, Steve Lam, to Direct Rapidly Expanding Business

DURHAM, NC, February 2, 2016 – Patheon today announced the appointment of Steve Lam as senior vice president of the company's biologics business. Lam will report to Lukas Utiger, president of the company's Drug Substance Services (DSS) segment, effective immediately. Biologics is a fast-growing area of the industry, which requires experience and expertise because of their complexity.

For the past 18 years, Lam has served as vice president of operations for Amgen, one of the world's leading independent biotechnology companies. He led a company-wide transformation initiative driving robust quality management processes and operational excellence. He brings to Patheon more than 25 years of leadership experience in biopharmaceutical operations with a focus on manufacturing and commercializing human therapeutics. He has specific expertise in protein manufacturing, cGMP compliance, quality systems and technology transfer.

"Our biologics business is an area with tremendous growth potential for Patheon," said Utiger. "With Steve's experience and his broad client perspective, he will energize our efforts and support our biopharmaceutical clients who are looking for a knowledgeable partner with scale and expertise to meet their needs. He will help us to continue to pursue strategies that capitalize on this expanding area of our business."

Lam's experience includes responsibility for lean manufacturing transformation and driving efforts toward greater efficiency. His efforts to improve manufacturing strategy, reduce risk and enhance product quality resulted in increased revenue while providing Amgen with new capabilities.

Lam earned a Bachelor of Arts degree in chemistry from Knox College in Galesburg, Illinois. He also attended the Executive Development Program at Northwestern University in Evanston, IL. He will be based at Patheon's offices in Boston.

About Patheon
Patheon is a leading global provider of outsourced pharmaceutical development and manufacturing services. With approximately 8,700 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle.


Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.